Salvage therapy for recurrent epithelial ovarian cancer.
There are no comparative prospective trials to support dogmatic statements concerning the sequence and duration of therapy in the salvage setting. Although the literature offers many examples of chemotherapy studies conducted in the salvage setting, these studies typically involve relatively small numbers of younger patients whose disease shows good performance. The extrapolation of these observations to the practice setting, compounded by the clinical and molecular heterogeneity of epithelial ovarian cancer, further exacerbates the difficulties encountered in individual treatment recommendations.
Baker
Vicki V
VV
Karmanos Cancer Institute, Wayne State University, 3990 John R. Hudson Building, Suite 4924, Detroit, MI 48201, USA. vbaker@med.wayne.edu
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D016879:Salvage Therapy
D000970:Antineoplastic Agents